Treating colorectal cancer in the biomarker era – what’s next?
Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
The role of antineoplastic drug in causing hypogonadism is poorly understood. The aim of this systematic review was to establish the prevalence, nature (pr
R. Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44, potential markers of osteosarcoma stem cells, and how further research may be warranted with…
The AML Hub spoke to Gege Gui, National Institutes of Health, Maryland, US. We asked, How does pretransplant IDH1 and IDH2 MRD affect posttransplant outcomes…
Medicine Advances is an open access general medical journal with a focus on new technologies, methods and products in the full life cycle of diseases.
The ESMO Academy continues to offer delegates a comprehensive, thorough update on the key topics in medical oncology
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses a survey comparing the use of CAR-T products axicabtagene ciloleucel (axi-cel) and tisagenlecleucel…
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
The investigational therapy IGNK001 has received orphan drug designation from the FDA for patients with acute myeloid leukemia.
Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.
Erin Frances Cobain, MD, highlights the current role of endocrine therapy and CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer.